" class="no-js "lang="en-US"> Freenome Archives - Medtech Alert
Monday, January 20, 2025

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Largest Clinical Study Validating A Blood-based Colorectal Screening Test Completes Enrollment

Freenome, a privately held biotech company, announced the completion of enrollment for PREEMPT CRC, the […]

Lance Baldo Joins Freenome as Chief Medical Officer

Freenome, a privately held biotech company, announced today that Lance Baldo, M.D. has joined the […]

Freenome Launches The Vallania Study For The Early Detection Of Multiple Cancers

Freenome, a privately held biotech company, today announced the initiation of Vallania, a clinical study […]

Freenome Presents Research Highlighting its Multiomics Blood Testing Platform in PREEMPT CRC

Freenome, a privately held biotech company, presented at the American Society of Clinical Oncology Gastrointestinal […]

Significant Investment Accelerates Freenome's Multiomics Platform for the Early Detection of Cancer

Freenome, a privately held biotech company, announced today that Roche has made an investment of $290 […]

Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection

Freenome, a privately held biotech company, today announced a Series D funding of $300 million. […]

Freenome Shows Continued Leadership in Colorectal Cancer Research

Freenome, a privately held biotech company, presented new research at the American College of Gastroenterology […]

New Study Finds Freenome ’s Multiomics Approach Successful in Detecting Pancreatic Cancer

Freenome, a privately-held biotech company, presented new research today at the American Association of Cancer […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more